Roche Holding AG (OTCMKTS:RHHBY) Receives Average Recommendation of “Moderate Buy” from Brokerages

Roche Holding AG (OTCMKTS:RHHBY) has been given a consensus rating of “Moderate Buy” by the twelve ratings firms that are presently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $60.00.

Several equities analysts have recently issued reports on RHHBY shares. HSBC reiterated a “hold” rating on shares of Roche in a research report on Thursday, September 10th. Royal Bank Of Canada started coverage on shares of Roche in a research note on Tuesday, September 8th. They set an “outperform” rating on the stock. Morgan Stanley raised shares of Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 price objective for the company in a report on Friday, August 7th. Finally, Zacks Research upgraded shares of Roche from a “strong sell” rating to a “hold” rating in a research report on Monday, August 24th.

Key Roche News

Here are the key news stories impacting Roche this week:

• Positive Sentiment: Roche and Genentech said the Lunsumio-based regimen met the primary endpoint in the Phase III CELESTIMO study for patients with previously treated follicular lymphoma. Lunsumio combined with Revlimid significantly improved progression-free survival compared with rituximab plus Revlimid, while reports also cited improved overall survival. The results strengthen the drug’s potential expansion in a major blood-cancer market and could support future revenue growth. Roche’s Lunsumio-based regimen significantly improves progression-free survival
• Positive Sentiment: Roche is partnering with Dualitas Therapeutics on bispecific-antibody research. The collaboration expands Roche’s drug-discovery capabilities and may create additional pipeline opportunities, although financial terms and the timing of potential products were not disclosed. Dualitas Therapeutics and Roche partner on bispecific antibody research
• Neutral Sentiment: Roche and Genentech opened an Innovation Center in Boston focused on cardiovascular, renal and metabolic diseases. The facility enhances the company’s research presence and collaboration network, but its financial benefits are longer term and are unlikely to materially affect near-term earnings. Roche announces the opening of its Boston Innovation Center
• Negative Sentiment: Coverage highlighting TG Therapeutics’ bullish momentum amid its ongoing rivalry with Roche underscores competitive risk in the hematology market. While the article does not report a new Roche setback, stronger rival positioning could limit market share or pricing power for Roche’s blood-cancer portfolio. TG Therapeutics makes a bullish move amid Roche rivalry

Hedge Funds Weigh In On Roche

Hedge funds have recently modified their holdings of the company. Confluence Investment Management LLC lifted its holdings in Roche by 1.2% in the 2nd quarter. Confluence Investment Management LLC now owns 20,925 shares of the company’s stock valued at $1,074,000 after acquiring an additional 258 shares during the last quarter. Enterprise Financial Services Corp raised its holdings in shares of Roche by 6.6% in the 1st quarter. Enterprise Financial Services Corp now owns 5,576 shares of the company’s stock worth $277,000 after purchasing an additional 345 shares in the last quarter. Archer Investment Corp increased its holdings in shares of Roche by 7.7% in the first quarter. Archer Investment Corp now owns 5,598 shares of the company’s stock valued at $278,000 after buying an additional 398 shares in the last quarter. Diversified Trust Co increased its holdings in shares of Roche by 0.8% in the first quarter. Diversified Trust Co now owns 59,375 shares of the company’s stock valued at $2,907,000 after buying an additional 448 shares in the last quarter. Finally, Fulton Bank N.A. lifted its position in shares of Roche by 5.1% during the 2nd quarter. Fulton Bank N.A. now owns 11,572 shares of the company’s stock valued at $597,000 after acquiring an additional 559 shares during the last quarter.

Roche Trading Down 0.9%

Shares of RHHBY opened at $54.63 on Friday. The firm has a fifty day moving average of $54.67 and a 200-day moving average of $52.44. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.38 and a quick ratio of 1.12. Roche has a 1 year low of $39.50 and a 1 year high of $60.85.

Roche Company Profile

Roche Holding AG is a Switzerland-based healthcare company that develops and provides pharmaceutical products and diagnostic solutions. Founded in 1896 and headquartered in Basel, Roche operates through two complementary divisions: Pharmaceuticals and Diagnostics.

The Pharmaceuticals division focuses on medicines for oncology, immunology, neuroscience, ophthalmology, hematology and other therapeutic areas. Its portfolio includes treatments such as Ocrevus, Hemlibra, Perjeta, Tecentriq and Vabysmo.